ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1178

Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: Abstract Number: 1007

Atopic Dermatitis and Risk of Incident Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1095

Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1060

B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 0996

Bacteria-Derived Indole Drives Autoimmune Arthritis by Altering B Cell Glycosylation of Autoantibodies

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1228

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Abstract Number: 1135

Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1362

BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1364

Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1352

Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1045

Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1197

Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: Abstract Number: 1229

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Abstract Number: 1118

Bone Marrow Lesion Scores in Patients with Knee Osteoarthritis Undergoing Tibial Osteotomy: Reliability and Concurrent Validity of the Knee Inflammation MRI Scoring System (KIMRISS)

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1336

Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].